NCT07933328
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
StatusNot Yet Recruiting
PhasePhase 2
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percent Change from Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat fraction (MRI-PDFF)
Timeframe: At Week 52
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Timeframe: Through Week 64
Severity of TEAEs
Timeframe: Through Week 64
Secondary (5)
Change from Baseline in Aspartate Aminotransferase (AST)
Change from Baseline in Alanine Aminotransferase (ALT)
Change from Baseline in FibroScan Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE)
Change from Baseline in Enhanced Liver Fibrosis (ELF)
Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP)
Arms and interventions
ALN-CIDEB Dose Level 1Experimental
ALN-CIDEB Dose Level 2Experimental
PlaceboPlacebo comparator
Drugs: ALN-CIDEB, Placebo